The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
916
February 18, 1994
View Complete Issue         Table of Contents 2019 
Terazosin for Benign Prostatic Hyperplasia
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Terazosin for Benign Prostatic Hyperplasia
February 18, 1994 (Issue: 916)
Terazosin (Hytrin - Abbott), a postsynaptic alpha 1 -adrenoreceptor blocker previ-ously available for treatment of hypertension (Medical Letter, 29:113, 1987), has now been approved by the US Food and Drug Administration (FDA) for treatment of...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Terazosin for Benign Prostatic Hyperplasia
Article code: 916a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.